243 related articles for article (PubMed ID: 11236942)
1. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
Rowley M; Liu P; Van Ness B
Blood; 2000 Nov; 96(9):3175-80. PubMed ID: 11050000
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
4. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.
Rowley M; Van Ness B
Oncogene; 2002 Dec; 21(57):8769-75. PubMed ID: 12483530
[TBL] [Abstract][Full Text] [Related]
5. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
7. Nonsecretory multiple myeloma.
Bourantas K
Eur J Haematol; 1996; 56(1-2):109-11. PubMed ID: 8599984
[No Abstract] [Full Text] [Related]
8. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
[TBL] [Abstract][Full Text] [Related]
9. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
11. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.
Croonquist PA; Linden MA; Zhao F; Van Ness BG
Blood; 2003 Oct; 102(7):2581-92. PubMed ID: 12791645
[TBL] [Abstract][Full Text] [Related]
12. Expression of BAX in plasma cell dyscrasias.
Renner S; Weisz J; Krajewski S; Krajewska M; Reed JC; Lichtenstein A
Clin Cancer Res; 2000 Jun; 6(6):2371-80. PubMed ID: 10873089
[TBL] [Abstract][Full Text] [Related]
13. Biology and therapy of multiple myeloma.
Barlogie B; Alexanian R
Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
[TBL] [Abstract][Full Text] [Related]
14. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
15. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
[TBL] [Abstract][Full Text] [Related]
16. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
Cells; 2022 May; 11(9):. PubMed ID: 35563880
[TBL] [Abstract][Full Text] [Related]
17. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
[TBL] [Abstract][Full Text] [Related]
18. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
[TBL] [Abstract][Full Text] [Related]
19. A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
Nara M; Suzuki K; Inoue Y; Enomoto H; Saito T; Fujioka S
Acta Haematol; 1993; 90(2):102-3. PubMed ID: 8285014
[No Abstract] [Full Text] [Related]
20. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
